Correlation between oritavancin and vancomycin minimum inhibitory concentrations in staphylococci

International Journal of Antimicrobial Agents

Volumn 40, Issue 6, 2012, Pages 562-563

  Arhin, Francis F ^a   Draghi, Deborah C ^b   Pillar, Chris M ^b,c   Moeck, Gregory ^a   Sahm, Daniel F ^b  

^a Medicines Company   (Canada)

^b Eurofins Medinet Inc   (Germany)

^c Micromyx LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALBAVANCIN; ORITAVANCIN; TELAVANCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; BACTERIUM ISOLATION; COAGULASE NEGATIVE STAPHYLOCOCCUS; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG POTENCY; LETTER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SPECIES DIFFERENTIATION; STAPHYLOCOCCUS AUREUS;

GLYCOPEPTIDES; HUMANS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS; VANCOMYCIN;

EID: 84869500580     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2012.06.019     Document Type: Letter

References (5)

1. G.A. McKay, S. Beaulieu, F.F. Arhin, A. Belley, I. Sarmiento, and T.R. Parr Jr. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium J Antimicrob Chemother 63 2009 1191 1199
2. F.F. Arhin, D.C. Draghi, C.M. Pillar, T.R. Parr Jr., G. Moeck, and D.F. Sahm Comparative in vitro activity profile of oritavancin against recent Gram-positive clinical isolates Antimicrob Agents Chemother 11 2009 4762 4771
3. R.N. Jones, H.S. Sader, T.R. Fritsche, P.A. Hogan, and D.J. Sheehan Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program J Clin Microbiol 44 2006 2622 2625 (Pubitemid 44092445)
4. J. Sliwinski, M. Precit, and R.-C. Mercier Relationship of in vitro MRSA strain characteristics to telavancin susceptibility: a multi-center evaluation 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 17-20 September 2011, Chicago, IL 2011 ASM Press Washington, DC [Abstract E1333]
5. F.F. Arhin, I. Sarmiento, T.R. Parr Jr., and G. Moeck Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin J Antimicrob Chemother 64 2009 868 870